SAB Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 06/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $1.3M | $2.2M | $23.9M | — |
| Research and development | $34.4M | $30.3M | $16.5M | $36.4M | — |
| Operating expenses | $49.0M | $44.2M | $40.3M | $52.8M | — |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | — |
| Interest expense | $240,664 | $318,401 | $315,284 | $301,584 | — |
| Pretax income | $13.3M | — | -$42.2M | -$18.7M | — |
| Income tax expense | $0 | $0 | $0 | $25,629 | — |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | — |
| Balance Sheet | |||||
| Cash and equivalents | $10.5M | $8.9M | $56.6M | $15.0M | $16.6M |
| Current assets | $101.1M | $23.8M | $58.9M | $22.1M | $28.0M |
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $59.4M |
| Current liabilities | $10.7M | $8.0M | $10.8M | $15.0M | $16.4M |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $22.3M |
| Stockholders' equity | $151.5M | $26.0M | $57.3M | $31.1M | $37.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$44.8M | -$34.3M | -$25.1M | -$23.5M | — |
| Depreciation and amortization | $3.0M | $4.7M | $3.7M | $3.2M | — |
| Stock-based compensation | $5.2M | $2.9M | $2.4M | $2.7M | — |
| Capital expenditure | $933,156 | $337,262 | $197,154 | $2.2M | — |
| Free cash flow | -$45.7M | -$34.6M | -$25.3M | -$25.6M | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 76.5M · Free float 64.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.